- Home
- QIPT vs IMUX Comparison
QIPT vs IMUX Comparison
Compare QIPT & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QIPT
- IMUX
- Stock Information
- Founded
- QIPT 1993
- IMUX 2016
- Country
- QIPT United States
- IMUX United States
- Employees
- QIPT N/A
- IMUX N/A
- Industry
- QIPT
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- QIPT
- IMUX Health Care
- Exchange
- QIPT Nasdaq
- IMUX Nasdaq
- Market Cap
- QIPT 118.5M
- IMUX 110.8M
- IPO Year
- QIPT N/A
- IMUX N/A
- Fundamental
- Price
- QIPT $2.36
- IMUX $1.11
- Analyst Decision
- QIPT Strong Buy
- IMUX Strong Buy
- Analyst Count
- QIPT 3
- IMUX 5
- Target Price
- QIPT $7.67
- IMUX $13.20
- AVG Volume (30 Days)
- QIPT 143.2K
- IMUX 931.7K
- Earning Date
- QIPT 12-16-2024
- IMUX 11-07-2024
- Dividend Yield
- QIPT N/A
- IMUX N/A
- EPS Growth
- QIPT N/A
- IMUX N/A
- EPS
- QIPT N/A
- IMUX N/A
- Revenue
- QIPT $244,231,000.00
- IMUX N/A
- Revenue This Year
- QIPT $24.53
- IMUX N/A
- Revenue Next Year
- QIPT $3.69
- IMUX N/A
- P/E Ratio
- QIPT N/A
- IMUX N/A
- Revenue Growth
- QIPT 29.31
- IMUX N/A
- 52 Week Low
- QIPT $2.35
- IMUX $0.97
- 52 Week High
- QIPT $5.29
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- QIPT 29.15
- IMUX 36.96
- Support Level
- QIPT $2.35
- IMUX $1.02
- Resistance Level
- QIPT $2.77
- IMUX $1.28
- Average True Range (ATR)
- QIPT 0.10
- IMUX 0.08
- MACD
- QIPT -0.03
- IMUX -0.00
- Stochastic Oscillator
- QIPT 3.23
- IMUX 35.29
About QIPT Quipt Home Medical Corp.
Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients. The company's services consist of Daily and Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea and PAP Treatment.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.